BRN Discussion Ongoing

buena suerte :-)

BOB Bank of Brainchip
June 10th, 2022 | 10:47 CEST

AI DRIVING GROWTH IN TECH STOCKS: APPLE, BRAINCHIP, AMAZON​

  • TECHNOLOGY
  • CHIPS
  • AI
Photo credits: pixabay.com
Apple is entering the healthcare market and unearthing a treasure trove of sensitive patient data that can improve the lives of many people around the world. The latest updates in hardware and software enable close monitoring of body vital signs and medication intake. A boon for families with, for example, parents with heart disease. To keep such highly sensitive data in safe places, Australian company BrainChip has an IP on the market that allows self-learning AI systems to stay right on the chip, secure as Fort Knox, free from the cloud. The exact opposite is bringing Amazon strong share price gains. Its web services help the share price jump rapidly.
time to read: 6 minutes | Author: Juliane Zielonka
ISIN: APPLE INC. | US0378331005 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , AMAZON.COM INC. DL-_01 | US0231351067

TABLE OF CONTENTS:​


Karim Nanji, CEO, Marble Financial


Full interview

Author
Juliane Zielonka

JULIANE ZIELONKA


Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

About the author

TAG CLOUD​


SHARES CLOUD​

APPLE - SCALING INTO THE AI-DRIVEN HEALTHCARE MARKET​

At this year's Worldwide Developers Conference, Apple (ISIN US0378331005) unveiled a new tool designed to facilitate medication tracking and other health-related functions. The "Medications" feature in the Health app is available on both the Apple Watch and the iPhone. It allows users to manage their medications, vitamins and supplements. The camera can scan a pill bottle and help you take your medication on time.
Apple users are very familiar with the artificial intelligence called "Siri." The built-in control assistant with the friendly female voice is activated via voice control and can execute light applications on cue. Like a virtual assistant, Siri can open applications on the iPhone, save notes, and call contacts.
Apple Health users are used to recording their steps. The Apple Watch already measures blood oxygen and heart rate and automatically switches to exercise records as soon as the motion sensors register a steady step rhythm. The built-in AI activates an emergency call system if a fall occurs and the Apple Watch wearer stops moving altogether.
The next innovative step especially helps people with chronic diseases to take their medication regularly. In the US, users can also receive alerts about potential drug interactions when they upload a new prescription. This tool is ideal for families who want to share medication data along with other health data. Thinking further, this creates logistics chains with mail-order pharmacies or medication delivery services.What at first glance seems like commercialization in the secondary healthcare market has the potential to make a breakthrough in digital health.
Apple has been supplying hospitals and doctors-in-training in the B2B segment for years. Future doctors are getting used to the iOS interface and its handling, so building a digital ecosystem around health data will only be a matter of time. The tech giant also announced that a new feature to detect atrial fibrillation will be available in watchOS 9. This is a heart condition that, if detected early, can be well treated.
The new FDA-approved feature will allow users to closely track their heart rhythm and determine if signs of atrial fibrillation are present.
And once a Siri gently whispers to move more, the more Siri learns from each user through body vital signs, the more likely it is to give digital AI a chance in terms of personal behavior change.
Even though tech is still shaken in the stock market, Tim Cook's vision of Apple becoming the health brand and pioneer in digital health is becoming a reality. Apple offers investors a good opportunity to capture the healthcare market through AI and Big Data.

BRAINCHIP - IP AS A BUSINESS MODEL FOR LEARNING AI SYSTEMS​

Artificial intelligence like Siri or Amazon's Alexa need memory to archive their learning. On the one hand, it needs semiconductors to create the physical space. On the other hand, learning successes are created by programmed algorithms that are able to continue changing themselves. This process is comparable to the human brain. The grey matter in the head is the physical location for the millions of nerve cells, which, depending on the training and application, continually reconnect and provide the appropriate output in their neuronal impulses.
Artificial intelligence with self-learning capabilities is the business of BrainChip Holdings. Its business model is based on licensing the intellectual property of this AI to achieve the greatest possible scale and reach.
BrainChip's flagship product Akida™ (ISIN AU0000BRN8) is the first neuromorphic processor IP on the market that mimics the human brain. Neuromorphic computers use architectures and principles similar to information processing in the brain. IT systems based on electronic models of neural circuits are called "neuromorphic." AI is executed locally on the chip, significantly reducing latency. By running processes directly on the chip, Akida is independent of cloud providers, which increases data privacy and security of applications. Cloud freedom allows data to be processed in place." Michael Dell, who has been very successful in the technology industry for some time, estimates that about 10% of all computing and data takes place on the chip. By 2025, he expects at least 75%. That is a significant shift," explains CEO Sean Hehir.
Wherever the greatest possible data security is required, technology like Akida is used. Be it in the healthcare sector with highly sensitive patient and drug data, cybersecurity technology companies or autonomous driving and electric mobility worldwide. Large corporations, intermediaries and SMEs form the target groups of BrainChip Holdings. The Australian company has already established partnerships with, for example, the Japanese semiconductor manufacturer MegaChips, which generally already develops highly complex AI and machine learning systems in-house. MegaChips focuses on automotive and industrial equipment growth areas, such as 5G communications infrastructure and factory automation. In addition, BrainChip serves mid-sized companies that want to deploy AI but only have a small developer team of three or four employees. This is where chip manufacturers or developers come in, and BrainChip provides them with its licensing model. The growth potential for neuromorphic AI systems that do not require the cloud is enormous. More information on the go-to-market strategy can be found here.

AMAZON - CLOUD BUSINESS GROWTH DRIVER​

In contrast to BrainChip's model, top dog Amazon (ISIN US0231351067) continues to focus on expanding its Amazon Web Services (AWS) in the cloud. E-commerce merchants, who care more about their business than their end customers' data security, are using the many tools available in the cloud-based offering. Amazon Web Services consists of more than 200 services, including telephony and machine learning. Companies that use AWS are Netflix, Facebook and Airbnb. They value the smooth flow of services for their own scaling.
If platform services like Netflix were to acquire their own servers, this could have a negative impact on profit forecasts because the international service would mean that they would have to build their own data centers worldwide. The "everything from a single source" model, or turnkey solution in technical jargon, continues to send Amazon's share price hurtling upward. In the first quarter of 2022, the AWS division grew revenue by 37% to EUR 17.2 billion. With a market share of 33%, Amazon is the leader in the cloud business, ahead of Microsoft and Alphabet.
With the artificial intelligence Alexa, Amazon succeeded in entering countless private households. However, the AI based on voice control has a disadvantage: through the connection to the Amazon Cloud, it becomes a privacy spy because Alexa listens to everything. One would rather have a device with an Akida chip for pure local data processing.

Tracking and collecting health data from the Quantified Self movement is coming of age. Apple in Cupertino succeeds in taking the next growth step in the huge health market. With the latest updates, Apple users are able to measure highly sensitive patient data to maintain and improve health themselves. For such purposes, Australian company BrainChip Holdings has developed a neuromorphic processor IP named Akida, which companies can use as a licensing model. The big advantage is that the local edge solution keeps the data in place. Security is one of the most important purchasing decisions for large corporations, especially in times of cyberattacks. On the other hand, Amazon is growing through its cloud business as it relieves platform-based companies such as Netflix, Airbnb and Facebook of needing to purchase data centers. The AWS division grew 37% in Q1 2022.
With a market share of 33%, Amazon is the leader in the cloud business, ahead of Microsoft and Alphabet.
With the artificial intelligence Alexa, Amazon succeeded in entering countless private households. However, the AI based on voice control has a disadvantage: through the connection to the Amazon Cloud, it becomes a privacy spy because Alexa listens to everything. One would rather have a device with an Akida chip for pure local data processing.
 
  • Like
  • Fire
Reactions: 26 users
D

Deleted member 118

Guest
Our new puppy "WAGS" graduating puppy school, just before we got covid. Her has been the best company whilst sick.
I didn’t think I could fall in love with a little dog after having bigger dogs all my life. But I still love my fat staffy as well.
E442238D-7D77-4F71-A586-B413E467320B.jpeg
C34BAD9E-491F-47CC-B5E9-0262E16708CA.jpeg
F2A35682-A89A-4E90-8D1F-000F9E6AE3D8.jpeg
B5B37043-9C88-456B-8EEB-7B9732E6A903.jpeg
 
  • Love
  • Like
Reactions: 22 users
Our new puppy "WAGS" graduating puppy school, just before we got covid. Her has been the best company whilst sick.
May you have a long a joyous life together with many special moments. Absolutely adorable 💕💕🥰
 
  • Love
  • Like
Reactions: 8 users

Galaxycar

Regular
I think the shorter forget that most people who hold either brought sub $0.40 so still way in the green,who definitely won’t sell or Brought above $0.80 and don’t want to take a loss that big so are prepared to hold. Either way they will be buying their own shares every day for the next two weeks,churning the price up and down get absolutely nowhere,Fuck 100 million shares is a hell of a target to buy back,good luck suckers
 
  • Like
  • Fire
  • Love
Reactions: 19 users
D

Deleted member 118

Guest

Attachments

  • CED6FE04-8557-453C-9EA3-A24F6D71B4EE.jpeg
    CED6FE04-8557-453C-9EA3-A24F6D71B4EE.jpeg
    108.3 KB · Views: 64
  • Like
  • Haha
Reactions: 4 users
  • Like
  • Love
Reactions: 6 users
  • Haha
  • Like
Reactions: 5 users
D

Deleted member 118

Guest
  • Haha
  • Like
Reactions: 3 users

Bravo

If ARM was an arm, BRN would be its biceps💪!
Perhaps someone could look for this patent to see if we can glean anything further from it? I would do it myself but I'm a bit tied up at the moment. And, no, I don't mean that in a kinky way @Rocket577! 🤭

View attachment 8928

Dear @Diogenese,

Could you please check into this patent (I have no idea where or how) when you have a spare minute or two? Thanks a million!

PS: Please try not to give me an ogre as I need to get a good sleep tonight!
 
  • Like
  • Haha
  • Fire
Reactions: 8 users

Proga

Regular
It was more along the lines of..

"Our hires will increase to around 100 total employees, so increasing our costs, but our increasing revenues, should match this"

So our outgoings, should remain fairly even, by the end of the year, but with a greatly increased ability, in all areas that matter, technology and sales.

They are building the foundations, for a Global tech giant, so breakeven and profit, may not come as quickly as we like, but the Company, will be growing and making big strides.

At least that's my take on what he said and what I hope to occur.

Keep in mind, that companys like Amazon and Tesla, only became profitable, in the last couple of years, but their share prices/market caps, were already huge by then..
It's impossible for BRN to give a definitive answer on revenue. It is out of BRN's hands. They know companies are working on applications using our technology but when they can get the chips manufactured and/or are prepared to go to market is the $64,000,000 question. We know Mercedes goes to market in 2024 but we don't know how many chips they'll be using with BRN technology in each vehicle. IMO they'll be using more per vehicle in their fully electric range.

There will also be companies coming out of left field using MegaChips, Renasas, Edge Impulse etc or their own skunk works like Panasonic or Sanyo. To change technology to Akida is a huge leap for these companies to make. It could make or break them.

Once they do go to market and revenue starts pouring in, times like today will be a distant memory. New revenue streams is the only way to bust open the current cycle but once it does, hold on to your hats. The dam will burst hard and fast. The stock will go through an incredible re-rating.

The only unknown is exactly when. My educated guess is anytime within the next 2 years. We probably won't see it coming until it hits because the companies using Akida will want to astonish their respective markets like Apple did with the iPhone.
 
  • Like
  • Fire
Reactions: 32 users

Boab

I wish I could paint like Vincent
June 10th, 2022 | 10:47 CEST

AI DRIVING GROWTH IN TECH STOCKS: APPLE, BRAINCHIP, AMAZON​

  • TECHNOLOGY
  • CHIPS
  • AI
Photo credits: pixabay.com
Apple is entering the healthcare market and unearthing a treasure trove of sensitive patient data that can improve the lives of many people around the world. The latest updates in hardware and software enable close monitoring of body vital signs and medication intake. A boon for families with, for example, parents with heart disease. To keep such highly sensitive data in safe places, Australian company BrainChip has an IP on the market that allows self-learning AI systems to stay right on the chip, secure as Fort Knox, free from the cloud. The exact opposite is bringing Amazon strong share price gains. Its web services help the share price jump rapidly.
time to read: 6 minutes | Author: Juliane Zielonka
ISIN: APPLE INC. | US0378331005 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , AMAZON.COM INC. DL-_01 | US0231351067

TABLE OF CONTENTS:​


Karim Nanji, CEO, Marble Financial


Full interview

Author
Juliane Zielonka

JULIANE ZIELONKA


Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

About the author

TAG CLOUD​


SHARES CLOUD​

APPLE - SCALING INTO THE AI-DRIVEN HEALTHCARE MARKET​

At this year's Worldwide Developers Conference, Apple (ISIN US0378331005) unveiled a new tool designed to facilitate medication tracking and other health-related functions. The "Medications" feature in the Health app is available on both the Apple Watch and the iPhone. It allows users to manage their medications, vitamins and supplements. The camera can scan a pill bottle and help you take your medication on time.
Apple users are very familiar with the artificial intelligence called "Siri." The built-in control assistant with the friendly female voice is activated via voice control and can execute light applications on cue. Like a virtual assistant, Siri can open applications on the iPhone, save notes, and call contacts.
Apple Health users are used to recording their steps. The Apple Watch already measures blood oxygen and heart rate and automatically switches to exercise records as soon as the motion sensors register a steady step rhythm. The built-in AI activates an emergency call system if a fall occurs and the Apple Watch wearer stops moving altogether.
The next innovative step especially helps people with chronic diseases to take their medication regularly. In the US, users can also receive alerts about potential drug interactions when they upload a new prescription. This tool is ideal for families who want to share medication data along with other health data. Thinking further, this creates logistics chains with mail-order pharmacies or medication delivery services.What at first glance seems like commercialization in the secondary healthcare market has the potential to make a breakthrough in digital health.
Apple has been supplying hospitals and doctors-in-training in the B2B segment for years. Future doctors are getting used to the iOS interface and its handling, so building a digital ecosystem around health data will only be a matter of time. The tech giant also announced that a new feature to detect atrial fibrillation will be available in watchOS 9. This is a heart condition that, if detected early, can be well treated.
The new FDA-approved feature will allow users to closely track their heart rhythm and determine if signs of atrial fibrillation are present.
And once a Siri gently whispers to move more, the more Siri learns from each user through body vital signs, the more likely it is to give digital AI a chance in terms of personal behavior change.
Even though tech is still shaken in the stock market, Tim Cook's vision of Apple becoming the health brand and pioneer in digital health is becoming a reality. Apple offers investors a good opportunity to capture the healthcare market through AI and Big Data.

BRAINCHIP - IP AS A BUSINESS MODEL FOR LEARNING AI SYSTEMS​

Artificial intelligence like Siri or Amazon's Alexa need memory to archive their learning. On the one hand, it needs semiconductors to create the physical space. On the other hand, learning successes are created by programmed algorithms that are able to continue changing themselves. This process is comparable to the human brain. The grey matter in the head is the physical location for the millions of nerve cells, which, depending on the training and application, continually reconnect and provide the appropriate output in their neuronal impulses.
Artificial intelligence with self-learning capabilities is the business of BrainChip Holdings. Its business model is based on licensing the intellectual property of this AI to achieve the greatest possible scale and reach.
BrainChip's flagship product Akida™ (ISIN AU0000BRN8) is the first neuromorphic processor IP on the market that mimics the human brain. Neuromorphic computers use architectures and principles similar to information processing in the brain. IT systems based on electronic models of neural circuits are called "neuromorphic." AI is executed locally on the chip, significantly reducing latency. By running processes directly on the chip, Akida is independent of cloud providers, which increases data privacy and security of applications. Cloud freedom allows data to be processed in place." Michael Dell, who has been very successful in the technology industry for some time, estimates that about 10% of all computing and data takes place on the chip. By 2025, he expects at least 75%. That is a significant shift," explains CEO Sean Hehir.
Wherever the greatest possible data security is required, technology like Akida is used. Be it in the healthcare sector with highly sensitive patient and drug data, cybersecurity technology companies or autonomous driving and electric mobility worldwide. Large corporations, intermediaries and SMEs form the target groups of BrainChip Holdings. The Australian company has already established partnerships with, for example, the Japanese semiconductor manufacturer MegaChips, which generally already develops highly complex AI and machine learning systems in-house. MegaChips focuses on automotive and industrial equipment growth areas, such as 5G communications infrastructure and factory automation. In addition, BrainChip serves mid-sized companies that want to deploy AI but only have a small developer team of three or four employees. This is where chip manufacturers or developers come in, and BrainChip provides them with its licensing model. The growth potential for neuromorphic AI systems that do not require the cloud is enormous. More information on the go-to-market strategy can be found here.

AMAZON - CLOUD BUSINESS GROWTH DRIVER​

In contrast to BrainChip's model, top dog Amazon (ISIN US0231351067) continues to focus on expanding its Amazon Web Services (AWS) in the cloud. E-commerce merchants, who care more about their business than their end customers' data security, are using the many tools available in the cloud-based offering. Amazon Web Services consists of more than 200 services, including telephony and machine learning. Companies that use AWS are Netflix, Facebook and Airbnb. They value the smooth flow of services for their own scaling.
If platform services like Netflix were to acquire their own servers, this could have a negative impact on profit forecasts because the international service would mean that they would have to build their own data centers worldwide. The "everything from a single source" model, or turnkey solution in technical jargon, continues to send Amazon's share price hurtling upward. In the first quarter of 2022, the AWS division grew revenue by 37% to EUR 17.2 billion. With a market share of 33%, Amazon is the leader in the cloud business, ahead of Microsoft and Alphabet.
With the artificial intelligence Alexa, Amazon succeeded in entering countless private households. However, the AI based on voice control has a disadvantage: through the connection to the Amazon Cloud, it becomes a privacy spy because Alexa listens to everything. One would rather have a device with an Akida chip for pure local data processing.

Tracking and collecting health data from the Quantified Self movement is coming of age. Apple in Cupertino succeeds in taking the next growth step in the huge health market. With the latest updates, Apple users are able to measure highly sensitive patient data to maintain and improve health themselves. For such purposes, Australian company BrainChip Holdings has developed a neuromorphic processor IP named Akida, which companies can use as a licensing model. The big advantage is that the local edge solution keeps the data in place. Security is one of the most important purchasing decisions for large corporations, especially in times of cyberattacks. On the other hand, Amazon is growing through its cloud business as it relieves platform-based companies such as Netflix, Airbnb and Facebook of needing to purchase data centers. The AWS division grew 37% in Q1 2022.
Great article(s). Nice find. Thank you
 
  • Like
  • Fire
  • Love
Reactions: 23 users
D

Deleted member 118

Guest
  • Like
  • Haha
Reactions: 4 users

Slade

Top 20
It's impossible for BRN to give a definitive answer on revenue. It is out of BRN's hands. They know companies are working on applications using our technology but when they can get the chips manufactured and/or are prepared to go to market is the $64,000,000 question. We know Mercedes goes to market in 2024 but we don't know how many chips they'll be using with BRN technology in each vehicle. IMO they'll be using more per vehicle in their fully electric range.

There will also be companies coming out of left field using MegaChips, Renasas, Edge Impulse etc or their own skunk works like Panasonic or Sanyo. To change technology to Akida is a huge leap for these companies to make. It could make or break them.

Once they do go to market and revenue starts pouring in, times like today will be a distant memory. New revenue streams is the only way to bust open the current cycle but once it does, hold on to your hats. The dam will burst hard and fast. The stock will go through an incredible re-rating.

The only unknown is exactly when. My educated guess is anytime within the next 2 years. We probably won't see it coming until it hits because the companies using Akida will want to astonish their respective markets like Apple did with the iPhone.
PVDM indicated that Renesas will produce a chip with Akida IP this year. I think we can expect it to come to market anytime in the next 5 months. Others please correct me if I have got this wrong. I think it was during his interview with the guy from the Commonwealth bank that he said this.
 
  • Like
Reactions: 18 users
D

Deleted member 118

Guest
PVDM indicated that Renesas will produce a chip with Akida IP this year. I think we can expect it to come to market anytime in the next 5 months. Others please correct me if I have got this wrong. I think it was during his interview with the guy from the Commonwealth bank that he said this.
 
  • Haha
  • Like
  • Fire
Reactions: 8 users

equanimous

Norse clairvoyant shapeshifter goddess
Dear @Diogenese,

Could you please check into this patent (I have no idea where or how) when you have a spare minute or two? Thanks a million!

PS: Please try not to give me an ogre as I need to get a good sleep tonight!
ogre.png

With a hunk of an ogre you will have sweet dreams
 
  • Haha
  • Like
Reactions: 7 users

Yak52

Regular
Actually we did he defrauded the boutique fund he set up of many millions and had to plead and was sentenced to 7 years.

My son was so upset by an elderly couple who had lost everything in his fraud as they reminded him of his grandparents that I am pretty sure that is why he went into regulation when he went to the UK.

And yes it would be fun to catch up.

Regards
FF
Sorry to hear about the fraudulent Fund Manager. Its amazing but when its about the Finance Industry there simply is no guarantee of integrity by those involved no matter who they are or at what level of finance they are involved in. Due diligence is the only possible safe guard against being fraudulently castrated!
I do hope that elderly couple were successful in getting recompense for what happened.
I currently am looking at a stock I invested in where it is likely all of us have been totally done over and will end in a 100% loss. Against complaints from stock holders ASX/ASIC have endorsed a Directors move in defrauding stockholders of a companies main assets. WA based mining stock which of course is no surprise at all. The story is not over yet but it looks gloomy for those stung and left with the pieces.
Sounds like a legal case but at which point do you stop throwing good money after bad?

ps. yes catching up one day would be enjoyable. You remind me in some ways of my ex who was a notable Lawyer from Melbourne in her days. She would be appalled at my use of words and the English language now! lol.

Yak52 :cool:
 
  • Like
  • Fire
  • Sad
Reactions: 9 users
PVDM indicated that Renesas will produce a chip with Akida IP this year. I think we can expect it to come to market anytime in the next 5 months. Others please correct me if I have got this wrong. I think it was during his interview with the guy from the Commonwealth bank that he said this.
And since he said this Sean Hehir has confirmed it but saying it was a suite of MCU’s.

My opinion only DYOR
FF

AKIDA BALLISTA
 
Last edited:
  • Like
  • Fire
Reactions: 21 users

Diogenese

Top 20
Dear @Diogenese,

Could you please check into this patent (I have no idea where or how) when you have a spare minute or two? Thanks a million!

PS: Please try not to give me an ogre as I need to get a good sleep tonight!
Sorry, I was away the day we did Mandarin.

This sounds like a mechanical contraction system to withdraw the LiDaR hump from the bonnet before you run over the peasants.

Chinese national patents which are not filed elsewhere usually have low inventive content.

Mustn't worry about ogre's - it's his day off.

1654857309974.png
 
  • Like
  • Haha
  • Love
Reactions: 28 users

Dozzaman1977

Regular
PVDM indicated that Renesas will produce a chip with Akida IP this year. I think we can expect it to come to market anytime in the next 5 months. Others please correct me if I have got this wrong. I think it was during his interview with the guy from the Commonwealth bank that he said this.

CEO Sean said in a interview quote "Renasas are Developing a SET of products, and as they start shipping those products we will collect royalties on these"

In the dictionary.....
SET = a collection of well defined objects (or in this case multiple products IMO)

Money GIF
 
  • Like
  • Fire
  • Love
Reactions: 32 users
Top Bottom